

with 0.07%, 0.29%, 0.01%, and 0.01%, respectively, in EBV-seropositive subjects (Figure 1A). Another important difference between our findings and those of the previous study is that the proportions of LCL-reactive cells in the $\gamma\delta$ T-cell and NK-cell populations were 0.3% and 0.2%, respectively, in our study (Figure 1B), compared with 21.7% and 38.9%, respectively, in the previous study.⁵

Because a proportion of cells within LCLs are lytically infected, the T-cell response to LCLs comprises responses to both lytic and latent EBV antigens. In our study, the mean frequency of lytically infected cells in 11 LCLs was 2.1%, as determined by expression of the immediate early protein BZLF1 measured with the BZ1 mAb (Santa Cruz Biotechnology). This is higher than the 0.6% level of lytic infection found by the earlier study.⁵ To reduce the possible effect of variability in the level of lytic infection on the T-cell response to LCLs, we used a PBMC/LCL ratio of 2:1, compared with 10:1 used in the previous study.⁵ Varying the PBMC/LCL ratio from 2:1 to 10:1 did not alter the LCL-specific frequencies in the CD4⁺ and CD8⁺ T-cell populations, but increasing the ratio to 20:1 decreased the frequencies. The differences between our results and those of Bhaduri-McIntosh et al may be due to technical differences in the assays used, such as a shorter incubation time of 6 hours compared with 20 hours and a longer LCL culture time of 3 months compared with 3–4 weeks, respectively.⁵ Our longer LCL culture time was used to avoid contamination of the LCL by EBV-specific T cells, which could falsely increase the recorded frequency of LCL-reactive cells in the tested populations. Furthermore, we studied nearly 4 times as many EBV-exposed subjects as the earlier study.⁵

Our finding that the frequency of EBV-specific T cells was much higher in the CD8⁺ T-cell population than the CD4⁺ T-cell population is consistent with previous studies using other assays.^{6–8} Studies using the IFN- γ ELISPOT assay to measure the response to autologous LCLs in fractionated T-cell populations of immune subjects reported that the frequency of LCL-specific T cells was 5–7 times higher in the CD8⁺ population than in the CD4⁺ population.^{6,7} Another study found that the frequency of CD4⁺ T cells responding to EBV-infected B-cell lysates in healthy EBV carriers⁸ was much lower than the frequency of CD8⁺ T cells specific for EBV epitopes.² Our finding that LCL-reactive cells constituted 1.6% of the CD8⁺ population in healthy immune subjects (Figure 1B) is similar to the 1.3% found by Yang et al using an IFN- γ ELISPOT assay.⁶ The great preponderance of CD8⁺ T cells over CD4⁺ T cells in the immune response to EBV in healthy EBV carriers is consistent with the massive expansion of CD8⁺ T cells, but not CD4⁺ T cells, during infectious mononucleosis⁹ and the role of EBV-specific CD8⁺ T cells as the principal effectors mediating regression of LCL outgrowth in healthy EBV carriers.¹⁰

Michael P. Pender

*The University of Queensland, School of Medicine and
Department of Neurology, Royal Brisbane and Women's Hospital,
Brisbane, Australia*

Peter A. Csurhes
*The University of Queensland, School of Medicine and
The University of Queensland Centre for Clinical Research,
Brisbane, Australia*

Casey M. M. Pfluger
*The University of Queensland, School of Medicine and
The University of Queensland Centre for Clinical Research,
Brisbane, Australia*

Scott R. Burrows
*The University of Queensland, School of Medicine and
Queensland Institute of Medical Research,
Brisbane, Australia*

Acknowledgments: The authors thank Dr Stefan Blum, Kaye Hooper, and Bernie Gazzard for assistance in the collection of blood samples. This work was supported by a project grant from Multiple Sclerosis Research Australia.

Contribution: M.P.P. planned the study, helped analyze the results, and wrote the manuscript; P.A.C. performed the laboratory studies and analyzed the data; C.M.M.P. assisted with the laboratory studies; S.R.B. helped plan the study and analyze the data; and all authors read and approved the final manuscript.

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Prof Michael P. Pender, Level 9, Health Sciences Building, Royal Brisbane and Women's Hospital, Brisbane, Queensland 4029, Australia; e-mail: m.pender@uq.edu.au; or Prof Scott R. Burrows, Cellular Immunology Laboratory, Queensland Institute of Medical Research, 300 Herston Road, Brisbane, Queensland 4029, Australia; e-mail: scott.burrows@qimr.edu.au.

References

1. Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. *Annu Rev Microbiol*. 2000;54:19-48.
2. Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein-Barr virus. *Annu Rev Immunol*. 2007;25:587-617.
3. Thorley-Lawson DA, Gross A. Persistence of the Epstein-Barr virus and the origins of associated lymphomas. *N Engl J Med*. 2004;350(13):1328-1337.
4. Pender MP. CD8+ T-cell deficiency, Epstein-Barr virus infection, vitamin D deficiency and steps to autoimmunity: a unifying hypothesis. *Autoimmune Dis*. 2012;2012:189096.
5. Bhaduri-McIntosh S, Rotenberg MJ, Gardner B, Robert M, Miller G. Repertoire and frequency of immune cells reactive to Epstein-Barr virus-derived autologous lymphoblastoid cell lines. *Blood*. 2008;111(3):1334-1343.
6. Yang J, Lemas VM, Flinn IW, Krone C, Ambinder RF. Application of the ELISPOT assay to the characterization of CD8+ responses to Epstein-Barr virus antigens. *Blood*. 2000;95(1):241-248.
7. Pender MP, Csurhes PA, Lenarczyk A, Pfluger CMM, Burrows SR. Decreased T cell reactivity to Epstein-Barr virus infected lymphoblastoid cell lines in multiple sclerosis. *J Neurol Neurosurg Psychiatry*. 2009;80(5):498-505.
8. Amyes E, Hatton C, Montamat-Sicotte D, et al. Characterization of the CD4+ T cell response to Epstein-Barr virus during primary and persistent infection. *J Exp Med*. 2003;198(6):903-911.
9. Odumade OA, Knight JA, Schmeling DO, Masopust D, Balfour HH Jr, Hogquist KA. Primary Epstein-Barr virus infection does not erode preexisting CD8+ T cell memory in humans. *J Exp Med*. 2012;209(3):471-478.
10. Gudgeon NH, Taylor GS, Long HM, Haigh TA, Rickinson AB. Regression of Epstein-Barr virus-induced B-cell transformation in vitro involves virus-specific CD8+ T cells as the principal effectors and a novel CD4+ T-cell reactivity. *J Virol*. 2005;79(9):5477-5488.

To the editor:

Significant weight gain in patients with chronic myeloid leukemia after imatinib therapy

Imatinib has had an impressive impact on the management of chronic myeloid leukemia (CML) patients, with the majority achieving durable complete cytogenetic responses, and, at present, tyrosine kinase inhibitor therapy is expected to be life-long. As a result of this dramatic change in the prognosis of CML, new

clinical and scientific challenges are to be met and the clinical focus now includes the management of long-term side effects.

It is anticipated that most patients with newly diagnosed hematologic malignancies will experience weight loss before and during the initial course of treatment because of a multifactorial

Table 1. Weight gain in CML patients after imatinib therapy

Months after imatinib therapy	N	Median weight gain (kg)	% weight gain	P	No. of patients with weight gain
6	48	3.4 (−6.0, 11.0)	4.8 (−5.3, 14.2)	< .0001	37 (77%)
12	45	4.1 (−3.1, 17.9)	5.3 (−4.2, 22.9)	< .0001	38 (84%)
18	43	4.7 (−3.4, 17.9)	6.3 (−4.8, 23.0)	< .0001	36 (84%)
24	35	5.2 (−8.4, 21.7)	6.2 (−12.0, 27.1)	< .0001	30 (83%)

CML indicates chronic myeloid leukemia.

process. The impact of imatinib therapy on body habitus in newly diagnosed patients with CML has not been previously reported. We conducted a retrospective analysis on weight change in newly diagnosed patients with CML in chronic phase (CP) subsequently treated with imatinib. Fifty adult patients with CML (median age 47.6 years [25-78]; male [n = 29], female [n = 21]) in CP were consecutively treated with 400 mg daily of imatinib and their weight analyzed at 6 monthly intervals for a period of 24 months. Patients were excluded if additional co-morbidities that could influence weight loss or gain were present, such as thyroid disorders, diabetes, and clinical fluid retention. The median weight at the start of imatinib therapy was 76.8 kg (range 49.7-123). There was a statistically significant gain in weight in evaluable patients even at 6 months ($P < .0001$), with more than 75% of patients gaining weight (Tables 1 and 2). The median BMI at the start of imatinib therapy was 26.3 kg (18.3-47.5). Our data show that even with a high starting percentage of by definition, obese (BMI > 30) patients (20%), the percentage of obese patients more than doubles by 18 months after the start of imatinib treatment, and is statistically significant.

Obesity is associated with increased cancer incidence and mortality. Complex molecular links exist between obesity and metabolic dysfunction. Imatinib principally targets the tyrosine kinase activity of BCR-ABL1, in addition to inhibitory effects on KIT, ARG, and platelet-derived growth factor receptor (PDGFR) kinases. Obesity is recognized to be associated with macrophage accumulation and inflammation in adipose tissue and macrophage-secreted factors have been reported to inhibit the differentiation of preadipocytes into adipocytes.¹ Macrophage-conditioned medium has been found to stimulate PDGFR tyrosine phosphorylation, which can be inhibited by the addition of imatinib. Inhibition of PDGFR by imatinib has been found to disrupt the prosurvival effect on preadipocyte survival. PDGF is also strongly implicated in atherosclerosis and stimulates proteoglycan synthesis, however imatinib reduces low-density lipoprotein binding in vitro and aortic deposition in vivo.² Imatinib has also been variably reported to have a favorable effect on glucose metabolism in diabetic patients, possibly by affecting insulin signaling pathways,³ protection against pancreatic cell death, and improved insulin sensitivity. Furthermore, imatinib has been reported to induce normalization of the

Table 2. Changes in BMI in CML patients during therapy with imatinib

BMI	Months after imatinib therapy				
	0	6	12	18	24
Non-obese	36 (80%)	29 (68%)	27 (68%)	22 (56%)	19 (58%)
Obese	9 (20%)	14 (32%)	13 (32%)	17 (44%)	14 (42%)
P value comparison with time 0		.18	.19	.02	.03

BMI indicates body mass index.

levels of serum cholesterol, triglycerides as well as low- and high-density lipoproteins. Mast cell disorders can be responsive to imatinib and it is notable that mast cells have been recognized to contribute to diet-induced obesity and diabetes.⁴

Therefore, it is apparent that the observed increase in weight of several patients treated with imatinib may be secondary to a complex etiology. Further prospective investigations aimed at investigating the molecular mechanisms of this metabolic effect and its clinical impact is warranted.

Elvis Aduwa

Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom

Richard Szydlo

Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom

David Marin

Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom

Letizia Foroni

Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom

Alistair Reid

Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom

John Goldman

Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom

Jane F. Apperley

Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom

Dragana Milojkovic

Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom

Acknowledgements: The authors are grateful for support from the National Institute of Health Research Biomedical Research Centre Funding Scheme (United Kingdom).

Conflict-of-interest disclosure: The authors declare no competing financial interests.

Correspondence: Dr Dragana Milojkovic, Department of Haematology, Imperial College London, Du Cane Road, London W12 0NN, United Kingdom; e-mail: d.milojkovic@imperial.ac.uk.

References

- Molgat AS, Gagnon A, Sorisky A. Preadipocyte apoptosis is prevented by macrophage-conditioned medium in a PDGF-dependent manner. *Am J Physiol Cell Physiol*. 2009;296(4):C757-C765.
- Ballinger ML, Osman N, Hashimura K, et al. Imatinib inhibits vascular smooth muscle proteoglycan synthesis and reduces LDL binding in vitro and aortic deposition in vivo. *J Cell Mol Med*. 2010;14(6B):1408-1418.
- Louvet C, Sztot GL, Lang J, et al. Tyrosine kinase inhibitors reverse type 1 diabetes in nonobese diabetic mice. *Proc Natl Acad Sci U S A*. 2008;105(48):18895-18900.
- Liu J, Divoux A, Sun J, et al. Genetic deficiency and pharmacological stabilization of mast cells reduce diet-induced obesity and diabetes in mice. *Nat Med*. 2009;15(8):940-945.